Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GEORGE J MURAKAWA

Allopathic & Osteopathic Physicians Dermatology

NPI
1265422497
CMS profile
102181
Location
TROY, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$53,796.10

238 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 238 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GEORGE J MURAKAWA

NPI 1265422497 · CMS profile ID 102181

Allopathic & Osteopathic Physicians / Dermatology

TROY, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 238 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265422497?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GEORGE J MURAKAWA, NPI 1265422497, CMS profile ID 102181. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 238 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265422497?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). GEORGE J MURAKAWA, NPI 1265422497, CMS profile ID 102181. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 238 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265422497?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
GEORGE J MURAKAWA, NPI 1265422497, CMS profile ID 102181, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 238 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1265422497?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

238 matching records · $53,796.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 238 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 238.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ortho Dermatologics, a division of Bausch Health US, LLC $23.8807/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153809399 CMS
Dermavant Sciences, Inc. $21.7607/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127909739 CMS
Galderma Laboratories, L.P. $117.6607/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145317713 CMS
Galderma Laboratories, L.P. $35.3407/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145317715 CMS
Galderma Laboratories, L.P. $33.0607/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145317717 CMS
Galderma Laboratories, L.P. $91.2107/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145317719 CMS
Galderma Laboratories, L.P. $172.6207/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145317721 CMS
Galderma Laboratories, L.P. $2,092.9507/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145317705 CMS
Galderma Laboratories, L.P. $678.0207/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145317707 CMS
Galderma Laboratories, L.P. $8.1107/26/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145317709 CMS
Galderma Laboratories, L.P. $251.9707/26/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145317711 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.1407/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117938699 CMS
Kyowa Kirin, Inc. $27.5407/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127030429 CMS
E.R. Squibb & Sons, L.L.C. $15.9707/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101811101 CMS
Novartis Pharmaceuticals Corporation $1.9007/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087081936 CMS
Kerecis Limited $25.2907/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120112669 CMS
LEO Pharma Inc. $14.2007/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152643587 CMS
PFIZER INC. $15.2707/08/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131656113 CMS
GENZYME CORPORATION $34.9707/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139658154 CMS
LEO Pharma Inc. $4.7406/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152643585 CMS
Galderma Laboratories, L.P. $9.7906/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145317703 CMS
Janssen Biotech, Inc. $5.2406/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078767672 CMS
Regeneron Healthcare Solutions, Inc. $12.3306/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114120214 CMS
Regeneron Healthcare Solutions, Inc. $32.9806/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114120216 CMS
Regeneron Healthcare Solutions, Inc. $60.0006/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114120218 CMS
Regeneron Healthcare Solutions, Inc. $70.0006/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114120220 CMS
Regeneron Healthcare Solutions, Inc. $18.9306/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114120222 CMS
Regeneron Healthcare Solutions, Inc. $51.4606/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114120224 CMS
UCB, Inc. $43.8506/24/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155578263 CMS
Regeneron Healthcare Solutions, Inc. $592.5006/21/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114120210 CMS
Regeneron Healthcare Solutions, Inc. $3,555.0006/21/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114120212 CMS
Janssen Scientific Affairs, LLC $94.0006/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078852826 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $82.9506/20/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152150813 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $25.4806/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152150829 CMS
UCB, Inc. $102.5306/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143120867 CMS
ABBVIE INC. $19.3006/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105083223 CMS
GENZYME CORPORATION $40.1806/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139658148 CMS
Regeneron Healthcare Solutions, Inc. $8,708.0006/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114120208 CMS
Novartis Pharmaceuticals Corporation $14.1906/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087081916 CMS
ABBVIE INC. $14.6806/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105083221 CMS
Amgen Inc. $13.2806/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117334956 CMS
LEO Pharma Inc. $20.2706/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152643583 CMS
GENZYME CORPORATION $5.7005/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139658140 CMS
Janssen Biotech, Inc. $3.2005/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078767262 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $24.5505/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152150827 CMS
GENZYME CORPORATION $128.0405/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139658120 CMS
Genentech USA, Inc. $19.0505/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133014342 CMS
Regeneron Healthcare Solutions, Inc. $25.5705/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114120206 CMS
Arcutis Biotherapeutics, Inc. $1.9405/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121048177 CMS
E.R. Squibb & Sons, L.L.C. $22.6605/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101811067 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,554.92 184
PY2020 $8,346.52 91
PY2021 $20,299.81 140
PY2022 $24,944.24 168
PY2023 $16,947.13 202
PY2024 $53,796.10 238
PY2025 $49,802.92 219

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,836.51 10
PY2025 Principal investigator $55,025.62 22
PY2024 Principal investigator $147,486.83 29
PY2023 Principal investigator $70,546.49 33
PY2022 Principal investigator $106,636.77 51
PY2021 Recipient $37.00 1
PY2021 Principal investigator $124,203.26 49
PY2020 Recipient $4,403.00 4
PY2020 Principal investigator $276,077.32 52
PY2019 Principal investigator $307,156.41 56

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,265.00 12/15/2025 Non-covered Recipient Entity
DERM CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175362146
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,265.25 11/25/2025 Non-covered Recipient Entity
DERM CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184264521
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
Somerset Skin Centre
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235993639
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,208.22 10/28/2025 Non-covered Recipient Entity
SOMERSET SKIN CENTER
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190304905
Principal investigator 1 Janssen Research & Development, LLC $3,193.00 10/27/2025 Non-covered Recipient Entity
DERM CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175362128
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 10/20/2025 Non-covered Recipient Entity
DERM CENTER
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184251536
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,745.31 10/09/2025 Non-covered Recipient Entity
DERM CENTER
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184248968
Principal investigator 1 Novartis Pharmaceuticals Corporation $453.78 10/08/2025 Non-covered Recipient Entity
SOMERSET SKIN CENTER
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190304907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 08/22/2025 Non-covered Recipient Entity
DERM CENTER
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184229973
Principal investigator 1 Janssen Research & Development, LLC $1,928.00 07/28/2025 Non-covered Recipient Entity
DERM CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175362108
Principal investigator 1 Janssen Research & Development, LLC $11,406.00 07/28/2025 Non-covered Recipient Entity
DERM CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175362115
Principal investigator 1 Janssen Research & Development, LLC $2,345.00 06/30/2025 Non-covered Recipient Entity
DERM CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175362101
Recipient Regeneron Pharmaceuticals, Inc. $53.20 06/27/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120809
Recipient Regeneron Pharmaceuticals, Inc. $64.00 06/27/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120811
Recipient Regeneron Pharmaceuticals, Inc. $51.86 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120795
Recipient Regeneron Pharmaceuticals, Inc. $57.46 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120797
Recipient Regeneron Pharmaceuticals, Inc. $98.90 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120799
Recipient Regeneron Pharmaceuticals, Inc. $103.02 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120801
Recipient Regeneron Pharmaceuticals, Inc. $127.07 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120803
Recipient Regeneron Pharmaceuticals, Inc. $351.03 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120805
Recipient Regeneron Pharmaceuticals, Inc. $418.88 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120807
Principal investigator 1 Janssen Research & Development, LLC $1,477.00 05/26/2025 Non-covered Recipient Entity
DERM CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175362075
Recipient Regeneron Pharmaceuticals, Inc. $511.09 04/29/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184120793
Principal investigator 1 Janssen Research & Development, LLC $2,345.00 04/28/2025 Non-covered Recipient Entity
DERM CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175362136
Principal investigator 1 Amgen Inc. $4,131.00 04/24/2025 Non-covered Recipient Entity
DERM CENTER
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246640695
Principal investigator 1 Janssen Research & Development, LLC $2,087.00 03/24/2025 Non-covered Recipient Entity
DERM CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175362122
Principal investigator 1 SANOFI US SERVICES INC. $2,200.00 03/17/2025 Non-covered Recipient Entity
Derm Center
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226082438
Principal investigator 1 Janssen Research & Development, LLC $2,954.00 03/03/2025 Non-covered Recipient Entity
DERM CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175362093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 02/20/2025 Non-covered Recipient Entity
DERM CENTER
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155106
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 02/20/2025 Non-covered Recipient Entity
DERM CENTER
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155108
Principal investigator 1 Amgen Inc. $6,483.77 01/27/2025 Non-covered Recipient Entity
SOMERSET SKIN CENTRE
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246648313
Principal investigator 1 Janssen Research & Development, LLC $3,882.00 01/27/2025 Non-covered Recipient Entity
DERM CENTER
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175362083